abstract |
The present invention relates to novel Factor VII or VIIa variants comprisin g a substitution in at least one position selected from the group consisting o f L39, 142, S43, K62, L65, F71, E82 and F275, which are positions involved in tissue factor binding. Such variants exhibit increased clotting activity as compared to human wild-type Factor VIIa. The present invention also relates to use of such Factor VII or VIIa variants in therapy, in particular for the treatment of a variety of coagulation-related disorders. |